<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Epilepsy Curr</journal-id>
<journal-id journal-id-type="iso-abbrev">Epilepsy Curr</journal-id>
<journal-id journal-id-type="publisher-id">EPI</journal-id>
<journal-id journal-id-type="hwp">spepi</journal-id>
<journal-title-group>
<journal-title>Epilepsy Currents</journal-title>
</journal-title-group>
<issn pub-type="ppub">1535-7597</issn>
<issn pub-type="epub">1535-7511</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31937124</article-id>
<article-id pub-id-type="pmc">7031802</article-id>
<article-id pub-id-type="doi">10.1177/1535759719895274</article-id>
<article-id pub-id-type="publisher-id">10.1177_1535759719895274</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Epilepsy Benchmarks Area II: Prevent Epilepsy and Its Progression</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Binder</surname>
<given-names>Devin K.</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff1-1535759719895274">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Boison</surname>
<given-names>Detlev</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff2-1535759719895274">2</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0001-9217-6393</contrib-id>
<name>
<surname>Eid</surname>
<given-names>Tore</given-names>
</name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff3-1535759719895274">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Frankel</surname>
<given-names>Wayne N.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff4-1535759719895274">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mingorance</surname>
<given-names>Ana</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff5-1535759719895274">5</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Smith</surname>
<given-names>Bret N.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff6-1535759719895274">6</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0003-1149-4192</contrib-id>
<name>
<surname>Dacks</surname>
<given-names>Penny A.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff7-1535759719895274">7</xref>
</contrib>
<contrib contrib-type="author">
<contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0000-0002-3980-9451</contrib-id>
<name>
<surname>Whittemore</surname>
<given-names>Vicky</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff8-1535759719895274">8</xref>
<xref ref-type="corresp" rid="corresp1-1535759719895274">*</xref>
<xref ref-type="author-notes" rid="fn1-1535759719895274"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Poduri</surname>
<given-names>Annapurna</given-names>
</name>
<degrees>MD, MPH</degrees>
<xref ref-type="aff" rid="aff9-1535759719895274">9</xref>
<xref ref-type="corresp" rid="corresp2-1535759719895274">*</xref>
<xref ref-type="author-notes" rid="fn1-1535759719895274"></xref>
</contrib>
<contrib contrib-type="author">
<collab>for the AES/NINDS Epilepsy Benchmarks Stewards</collab>
</contrib>
</contrib-group>
<aff id="aff1-1535759719895274">
<label>1</label>Division of Biomedical Sciences, School of Medicine, Center for Glial-Neuronal Interactions, University of California, Riverside, CA, USA</aff>
<aff id="aff2-1535759719895274">
<label>2</label>Department of Neurosurgery, Robert Wood Johnson and New Jersey Medical Schools, Rutgers University, Piscataway, NJ, USA</aff>
<aff id="aff3-1535759719895274">
<label>3</label>Department of Laboratory Medicine, Neurosurgery and Molecular Physiology, Yale University, New Haven, CT, USA</aff>
<aff id="aff4-1535759719895274">
<label>4</label>Department of Genetics &amp; Development, Institute for Genomic Medicine, Columbia University Irving Medical Center, New York, NY, USA</aff>
<aff id="aff5-1535759719895274">
<label>5</label>Dracaena Consulting SL, Madrid, Spain</aff>
<aff id="aff6-1535759719895274">
<label>6</label>Department of Neuroscience, University of Kentucky College of Medicine, Lexington, KY, USA</aff>
<aff id="aff7-1535759719895274">
<label>7</label>American Epilepsy Society, Chicago, IL, USA</aff>
<aff id="aff8-1535759719895274">
<label>8</label>Division of Neuroscience, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA</aff>
<aff id="aff9-1535759719895274">
<label>9</label>Epilepsy Genetics Program, Department of Neurology, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA</aff>
<author-notes>
<corresp id="corresp1-1535759719895274"><label>*</label>Vicky Whittemore, National Institute of Neurological Disorders and Stroke, 6001 Executive Boulevard, NSC Room 2133, Bethesda, MD 20852, USA; e-mail: <email>vicky.whittemore@nih.gov</email></corresp>
<corresp id="corresp2-1535759719895274"><label>*</label>Annapurna Poduri, Boston Children’s Hospital, 300 Longwood Avenue, Fegan, Boston, MA 02115, USA; e-mail: <email>annapurna.Poduri@childrens.harvard.edu</email></corresp>
<fn fn-type="other" id="fn1-1535759719895274">
<p>Vicky Whittemore and Annapurna Poduri are Co-Chairs of the NINDS/AES Epilepsy Research Benchmark Stewards Committee.</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>15</day>
<month>1</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<season>Jan-Feb</season>
<year>2020</year>
</pub-date>
<volume>20</volume>
<issue>1 Suppl</issue>
<fpage>14S</fpage>
<lpage>22S</lpage>
<permissions>
<copyright-statement>© The Author(s) 2020</copyright-statement>
<copyright-year>2020</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
<license license-type="creative-commons" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
<license-p>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">https://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>) which permits non-commercial use, reproduction and distribution of the work as published without adaptation or alteration, without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p>
</license>
</permissions>
<abstract>
<p>Area II of the 2014 Epilepsy Research Benchmarks aims to establish goals for preventing the development and progression of epilepsy. In this review, we will highlight key advances in Area II since the last summary of research progress and opportunities was published in 2016. We also highlight areas of investigation that began to develop before 2016 and in which additional progress has been made more recently.</p>
</abstract>
<kwd-group>
<kwd>preventing epilepsy</kwd>
<kwd>epilepsy prevention</kwd>
<kwd>prevention clinical trials</kwd>
<kwd>epileptogenesis</kwd>
<kwd>NINDS benchmarks for epilepsy research</kwd>
<kwd>epilepsy</kwd>
<kwd>benchmarks</kwd>
<kwd>progress in epilepsy research</kwd>
</kwd-group>
<funding-group>
<award-group id="award1-1535759719895274">
<funding-source id="funding1-1535759719895274">
<institution-wrap>
<institution>National Institute of Neurological Disorders and Stroke</institution>
<institution-id institution-id-type="FundRef">https://doi.org/10.13039/100000065</institution-id>
</institution-wrap>
</funding-source>
<award-id rid="funding1-1535759719895274">NS065957</award-id>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>January-February 2020</meta-value>
</custom-meta>
<custom-meta>
<meta-name>typesetter</meta-name>
<meta-value>ts3</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="section1-1535759719895274">
<title>Introductory Vignette by Shelly Meitzler. Can Epilepsy Be Prevented?</title>
<p>Two of my 3 children have tuberous sclerosis complex (TSC). Ashlin is 18 and Mason is 6. Because of recent research discoveries, their hopes for the future are entirely different.</p>
<p>Ashlin experienced her first seizure at 4 months old and, 4 agonizing weeks later, TSC was confirmed as her diagnosis. I felt defeated as multiple seizures, hospitalizations, life flights, countless failed medications, and endless testing dictated daily life. Status epilepticus when Ashlin was two and a half years old ripped away a piece of my child forever. She came home after a 10-day hospital stay with right-sided paralysis, no vocabulary, the inability to feed herself, sit up, crawl, or walk. She sees 10 different specialists, receives in-home therapy 5 days a week, will require assisted care for the duration of her life, and takes 18 doses of 7 different medications to treat the varying manifestations of TSC.</p>
<p>Mason was diagnosed with TSC at 7 months old. He was promptly enrolled in a research study at Boston Children’s Hospital, which has been invaluable to Mason’s developmental progress. When his infantile spasms began, vigabatrin was started within 6 days, and we’ve not seen an infantile spasm since. Mason experienced status epilepticus in March 2015 and required so much rescue medication, a code blue was called to resuscitate him. Fortunately, he recovered with no major setbacks.</p>
<p>Over the past 18 years, I’ve witnessed so much progress and, because of additional options now available, I have so much more hope for Mason’s future. While the TSC community is grateful for current treatment options, they do not work for everyone, and the long-term need is to prevent manifestations before onset. We have made huge progress in terms of research and new treatments, but we have more work to do and more answers to find.</p>
<p>Shelly Meitzler of Tuberous Sclerosis Alliance</p>
</sec>
<sec id="section2-1535759719895274" sec-type="intro">
<title>Introduction</title>
<p>Area II of the 2014 Epilepsy Research Benchmarks aimed to establish goals for preventing the development and progression of epilepsy. In this review, we will highlight some key advances in Area II since the last summary of research progress and opportunities in this area was published in 2016<sup><xref ref-type="bibr" rid="bibr1-1535759719895274">1</xref></sup> as well as some areas of investigation that began to develop before 2016 and in which additional progress has been made more recently.</p>
</sec>
<sec id="section3-1535759719895274">
<title>New Insights into Mechanisms and Modulators of Acquired Epileptogenesis</title>
<p>In the following sections, we summarize 3 themes in research in antiepileptogenic mechanisms: metabolic mechanisms, epigenetic mechanisms, and astrocyte-specific processes that influence epileptogenesis.</p>
<sec id="section4-1535759719895274">
<title>Metabolic Mechanisms</title>
<p>The role of metabolism is an emerging area of epilepsy research. In addition to epilepsy being the direct consequence of pathogenic variants in genes encoding proteins in epilepsy disorders, such as in glucose transporter type 1 deficiency syndromes,<sup><xref ref-type="bibr" rid="bibr2-1535759719895274">2</xref></sup> it has been shown that maladaptive changes in metabolism contribute to epilepsy development.<sup><xref ref-type="bibr" rid="bibr3-1535759719895274">3</xref></sup> Conversely, metabolic therapeutic approaches, such as the ketogenic diet (KD), have been shown (1) to influence the epigenome and (2) to prevent epileptogenesis.<sup><xref ref-type="bibr" rid="bibr4-1535759719895274">4</xref><xref ref-type="bibr" rid="bibr5-1535759719895274"></xref><xref ref-type="bibr" rid="bibr6-1535759719895274"></xref><xref ref-type="bibr" rid="bibr7-1535759719895274"></xref>-<xref ref-type="bibr" rid="bibr8-1535759719895274">8</xref></sup> The KD suppresses seizures in some patients, reflecting the antiepileptic effects of specific metabolic changes.<sup><xref ref-type="bibr" rid="bibr4-1535759719895274">4</xref>,<xref ref-type="bibr" rid="bibr6-1535759719895274">6</xref>,<xref ref-type="bibr" rid="bibr9-1535759719895274">9</xref></sup> Mechanisms underlying the success of the KD are the subject of intense research efforts. Dietary compliance is difficult for many individuals on the KD, and lack of complete adherence to this diet can obviate the potential benefits of treatment. Some recent studies have focused on the specific effects of medium-chain triglycerides, both as a component of the KD<sup><xref ref-type="bibr" rid="bibr9-1535759719895274">9</xref></sup> and independently<sup><xref ref-type="bibr" rid="bibr10-1535759719895274">10</xref></sup> on both metabolic and antiepileptic effects. Others have suggested that effects of ketone bodies themselves on mitochondrial metabolism may underlie antiseizure effects of the KD, for example, in <italic>Kcna1</italic>-null mice.<sup><xref ref-type="bibr" rid="bibr11-1535759719895274">11</xref></sup> There has been recent progress toward understanding some of the mechanisms of action of the KD, such as AMPA receptor inhibition.<sup><xref ref-type="bibr" rid="bibr12-1535759719895274">12</xref></sup> In parallel, there are efforts to include modifications in the diet to make it more tolerable for people with epilepsy.<sup><xref ref-type="bibr" rid="bibr13-1535759719895274">13</xref></sup></p>
<p>Traditional antiseizure medication screening has been largely biased toward transmembrane channels and receptors, yet intracellular proteins and enzymes may represent appropriate therapeutic targets. Recently, several studies have emerged demonstrating proof-of-principle for metabolic targets as novel antiseizure medications or antiepileptogenic drugs. One study used a novel screening platform involving in vivo bioenergetics screening assays to uncover therapeutic agents that improve mitochondrial health; using an 870-compound screen in <italic>kcna1</italic>-morpholino zebrafish larvae, vorinostat (an histone deacetylase [HDAC] inhibitor) was uncovered as a potent antiseizure agent.<sup><xref ref-type="bibr" rid="bibr14-1535759719895274">14</xref></sup> This study provides proof-of-principle for metabolism-based experimental therapeutics in epilepsy. Similarly, a study of glucose metabolism in <italic>SCN1Lab</italic> mutant zebrafish (a model of Dravet syndrome, DS) identified a decrease in baseline glycolytic rate and oxygen consumption rate which was rescued by KD, suggesting that mitochondrial hypometabolism contributes to the pathophysiology of DS.<sup><xref ref-type="bibr" rid="bibr15-1535759719895274">15</xref></sup> Inhibition of lactate dehydrogenase (LDH), a component of the astrocyte-neuron lactate shuttle, hyperpolarized neurons and suppressed seizures in vivo indicating that LDH inhibition may represent a promising antiepileptic target.<sup><xref ref-type="bibr" rid="bibr16-1535759719895274">16</xref></sup> Together, the above and other studies indicate that as our knowledge of specific metabolic manipulations deepens, novel antiepileptic targets for various types of acquired epilepsy are likely to emerge.<sup><xref ref-type="bibr" rid="bibr17-1535759719895274">17</xref>,<xref ref-type="bibr" rid="bibr18-1535759719895274">18</xref></sup> Various dietary or pharmacological therapies may also modify the gut microbiome,<sup><xref ref-type="bibr" rid="bibr19-1535759719895274">19</xref><xref ref-type="bibr" rid="bibr20-1535759719895274"></xref>-<xref ref-type="bibr" rid="bibr21-1535759719895274">21</xref></sup> which may have indirect effects on brain excitability. Indeed, “dysbiosis” may underlie some forms of drug-resistant epilepsy,<sup><xref ref-type="bibr" rid="bibr22-1535759719895274">22</xref></sup> and a more systemic or “metabolic” viewpoint should be adopted to attempt to develop novel antiepileptogenic strategies that may initially seem “far from the synapse.” This area requires more investigation to determine whether there will be evidence to support some of the novel hypotheses related to the microbiome.</p>
</sec>
<sec id="section5-1535759719895274">
<title>Epigenetic Mechanisms</title>
<p>The role of histone modification in contributing to various neurological diseases including epilepsy is under intense study. Modification of chromatin structure has been implicated in learning, memory, and synaptic plasticity; and recent studies suggest translational relevance to epilepsy. For example, in a mouse model of tuberous sclerosis complex (TSC), decreased hippocampal histone H3 acetylation levels were observed; HDAC inhibition restored histone H3 acetylation, normalized synaptic plasticity, and suppressed seizures.<sup><xref ref-type="bibr" rid="bibr23-1535759719895274">23</xref></sup> Interestingly, daily treatment with the HDAC inhibitor sodium butyrate inhibited hippocampal kindling epileptogenesis.<sup><xref ref-type="bibr" rid="bibr24-1535759719895274">24</xref></sup> Other mouse models of temporal lobe epilepsy (TLE), such as the kainic acid and pilocarpine models, also demonstrate altered histone acetylation, HDAC expression, and DNA methylation.<sup><xref ref-type="bibr" rid="bibr5-1535759719895274">5</xref>,<xref ref-type="bibr" rid="bibr25-1535759719895274">25</xref><xref ref-type="bibr" rid="bibr26-1535759719895274"></xref>-<xref ref-type="bibr" rid="bibr27-1535759719895274">27</xref></sup> Beyond mouse models of epilepsy, another approach is to obtain surgically resected brain tissue from patients with drug-resistant epilepsy and perform genome-wide CpG-DNA methylation profiling to evaluate for specific epigenetic signatures. In one study using this approach, tissue from a patient with focal cortical dysplasia type II was found to demonstrate an epigenetic signature that identified candidate genes and pathways involved in pathogenesis.<sup><xref ref-type="bibr" rid="bibr28-1535759719895274">28</xref></sup> Similarly, methylation analysis reveals specific profiles of TLE with or without hippocampal sclerosis,<sup><xref ref-type="bibr" rid="bibr29-1535759719895274">29</xref></sup> and increased expression of DNA methyltransferases has been observed in human TLE.<sup><xref ref-type="bibr" rid="bibr30-1535759719895274">30</xref></sup> Investigators have also tested the ability of induced epigenetic modification to prevent epileptogenesis. The endogenous anticonvulsant adenosine causes DNA hypomethylation by biochemical interference with the transmethylation pathway, and adenosine and/or adenosine kinase inhibition inhibits epileptogenesis in multiple seizure models.<sup><xref ref-type="bibr" rid="bibr31-1535759719895274">31</xref>,<xref ref-type="bibr" rid="bibr32-1535759719895274">32</xref></sup> Thus, pathological changes in DNA methylation may underlie certain forms of epileptogenesis, and reversal of these epigenetic changes may represent a key antiepileptogenic strategy. The currently used antiepileptic drug valproic acid is also known to be an HDAC inhibitor,<sup><xref ref-type="bibr" rid="bibr33-1535759719895274">33</xref></sup> and its effects could be compared to some of the novel strategies that emerge in this area. Overall, the above studies suggest a role for chromatin modification in various forms of epilepsy, suggesting novel therapeutic strategies focused on normalizing chromatin structure. Profiling specific pathogenic epigenetic modifications may eventually allow more personalized approaches to treatment for specific epilepsy syndromes.</p>
</sec>
<sec id="section6-1535759719895274">
<title>Astrocyte-Mediated Mechanisms</title>
<p>Astrocytes play an established role in removal of glutamate at synapses and the sequestration and redistribution of K<sup>+</sup> and H<sub>2</sub>O during neural activity. It is becoming increasingly clear that changes in astrocyte channels, transporters, and metabolism play a direct role in seizure susceptibility and the development of epilepsy.<sup><xref ref-type="bibr" rid="bibr34-1535759719895274">34</xref></sup> Stimulation of astrocytes leads to prolonged neuronal depolarization and epileptiform discharges.<sup><xref ref-type="bibr" rid="bibr35-1535759719895274">35</xref></sup> Astrocytes release neuroactive molecules and modulate synaptic transmission through modifications in channels, gap junctions, receptors, and transporters. Further, striking changes in astrocyte form and function occur in epilepsy. Astrocytes adopt reactive morphology, become uncoupled, and lose domain organization in epileptic tissue. These and other changes—such as changes in the expression of the astrocytic enzymes adenosine kinase and glutamine synthetase, astroglial proliferation, dysregulation of ion channel and glutamate transporter expression, alterations in secretion of neuroactive molecules, increased activation of inflammatory pathways, and aberrant activation of mammalian target of rapamycin (mTOR) signaling—may all contribute to hyperexcitability and epileptogenesis.<sup><xref ref-type="bibr" rid="bibr36-1535759719895274">36</xref></sup></p>
<p>Two specific examples of astrocyte involvement in epileptogenesis include:<list list-type="order"><list-item><p><italic>Tuberous sclerosis complex</italic>: Evidence using astrocyte-specific <italic>Tsc1</italic> conditional knockout mice (mice in which the gene is knocked out only in astrocytes) has provided insight into a potential role of astrocytes in the etiology of TSC. These <italic>Tsc1</italic><sup>GFAP</sup>cKO mice develop severe spontaneous seizures by 2 months of age and die prematurely.<sup><xref ref-type="bibr" rid="bibr37-1535759719895274">37</xref></sup> The time of onset of spontaneous seizures in these mice is concordant with increased astroglial proliferation. Further, 2 functions of astrocytes—glutamate and K<sup>+</sup> reuptake—are impaired in these mice, which also display reduced expression of the astrocyte glutamate transporters GLT1 and GLAST.<sup><xref ref-type="bibr" rid="bibr38-1535759719895274">38</xref></sup> In addition, recent evidence indicates that astrocytes from <italic>Tsc1</italic><sup>GFAP</sup>cKO mice exhibit reduced activity of inwardly rectifying K<sup>+</sup> channels, and hippocampal slices from these mice demonstrated increased sensitivity to K<sup>+</sup>-induced epileptiform activity.<sup><xref ref-type="bibr" rid="bibr39-1535759719895274">39</xref></sup> A more recent inducible <italic>Tsc1</italic> knockout mouse in which <italic>Tsc1</italic> gene inactivation in GFAP-expressing cells was induced at 2 weeks of age was sufficient to cause astrogliosis and mild epilepsy (with a less severe phenotype than with prenatal <italic>Tsc1</italic> gene inactivation).<sup><xref ref-type="bibr" rid="bibr40-1535759719895274">40</xref></sup> Together, these studies demonstrate that in this model, changes in glial properties may be a direct cause of epileptogenesis.</p></list-item><list-item><p><italic>Posttraumatic epilepsy</italic>: Posttraumatic epilepsy (PTE) refers to a recurrent seizure disorder whose cause is traumatic brain injury (TBI). Posttraumatic epilepsy develops in a variable proportion of TBI survivors depending on the severity of the injury and the time after injury.<sup><xref ref-type="bibr" rid="bibr41-1535759719895274">41</xref>,<xref ref-type="bibr" rid="bibr42-1535759719895274">42</xref></sup> Antiseizure medication prophylaxis is ineffective at preventing the occurrence of late seizures.<sup><xref ref-type="bibr" rid="bibr43-1535759719895274">43</xref><xref ref-type="bibr" rid="bibr44-1535759719895274"></xref>-<xref ref-type="bibr" rid="bibr45-1535759719895274">45</xref></sup> Various animal models of PTE have demonstrated characteristic structural and functional changes in the hippocampus, such as death of dentate hilar neurons, increased dentate granule cell neurogenesis, mossy fiber sprouting, synaptic reorganization of dentate granule cells and CA3 pyramidal cells, and altered γ-aminobutyric acid receptor signaling.<sup><xref ref-type="bibr" rid="bibr46-1535759719895274">46</xref><xref ref-type="bibr" rid="bibr47-1535759719895274"></xref><xref ref-type="bibr" rid="bibr48-1535759719895274"></xref><xref ref-type="bibr" rid="bibr49-1535759719895274"></xref><xref ref-type="bibr" rid="bibr50-1535759719895274"></xref><xref ref-type="bibr" rid="bibr51-1535759719895274"></xref><xref ref-type="bibr" rid="bibr52-1535759719895274"></xref>-<xref ref-type="bibr" rid="bibr53-1535759719895274">53</xref></sup> Studies have also implicated altered astrocyte function in PTE models, including impaired K<sup>+</sup> homeostasis in posttraumatic hippocampal glia<sup><xref ref-type="bibr" rid="bibr54-1535759719895274">54</xref></sup> and impaired astrocyte glutamate transport in a PTE model induced by intracortical ferrous chloride injection.<sup><xref ref-type="bibr" rid="bibr55-1535759719895274">55</xref></sup> Further studies of the role of glial cells appear warranted with advances in the past decade on PTE animal models.<sup><xref ref-type="bibr" rid="bibr56-1535759719895274">56</xref></sup> In particular, long-term changes in astrocyte channels and transporters after TBI that may correlate with PTE should be investigated. Recently, new models of repetitive diffuse mild closed-head TBI in mice have been described that are sufficient to cause PTE;<sup><xref ref-type="bibr" rid="bibr57-1535759719895274">57</xref>,<xref ref-type="bibr" rid="bibr58-1535759719895274">58</xref></sup> interestingly, in one study classic astrogliosis was limited but a population of atypical reactive astrocytes was identified that correlated with the subset of mice that developed PTE.<sup><xref ref-type="bibr" rid="bibr58-1535759719895274">58</xref></sup> This new study suggests that, in addition to well-described neuronal dysfunction, astrocyte morphological, structural, functional, and molecular changes may contribute to or underlie PTE.</p></list-item></list></p>
<p>Since TBI is associated with breakdown of the blood–brain barrier (BBB) at the time of the initial event, studies of BBB disruption-induced epileptogenesis are also relevant to mechanisms of PTE. Indeed, transient opening of the BBB is sufficient for focal epileptogenesis.<sup><xref ref-type="bibr" rid="bibr59-1535759719895274">59</xref></sup> Extravasated albumin can be taken up by astrocytes, which activates the transforming growth factor-β (TGF-β) pathway leading to focal epileptogenesis and excitatory synaptogenesis through astrocyte TGF-β/ALK5 signaling.<sup><xref ref-type="bibr" rid="bibr60-1535759719895274">60</xref></sup> This mechanism provides an astrocytic basis for BBB disruption-induced epileptogenesis and suggests antiepileptogenic therapeutic approaches (TGF-β inhibition). Indeed, TGF-β inhibition through treatment with losartan, an angiotensin-II receptor antagonist and Food and Drug Administration (FDA)-approved antihypertensive medication, was found to exert antiepileptogenic effects in these BBB disruption models.<sup><xref ref-type="bibr" rid="bibr61-1535759719895274">61</xref><xref ref-type="bibr" rid="bibr62-1535759719895274"></xref>-<xref ref-type="bibr" rid="bibr63-1535759719895274">63</xref></sup> It will be of interest in the future to test similar strategies in PTE models for antiepileptogenic efficacy.</p>
</sec>
</sec>
<sec id="section7-1535759719895274">
<title>New Targets/Opportunities for Antiepileptogenic Therapies</title>
<sec id="section8-1535759719895274">
<title>Repurposing of FDA-Approved Drugs</title>
<p>Current antiseizure medications have several shortcomings: both in terms of efficacy, failing to control seizures in about one-third of cases, and tolerability, with many associated with adverse cognitive, behavioral, or other side effects. Repurposing of existing FDA-approved drugs to treat epilepsy and/or epilepsy-associated comorbidities may offer some advantages. First, there would be savings in time and cost of drug development. Second, the risk profile of an FDA-approved drug may already be understood and may be very different than current antiseizure medications. Third, existing drugs may be targeted based on specific aspects of cellular or network dysfunction that occur in epilepsy. Several recent studies have proposed such an approach.<sup><xref ref-type="bibr" rid="bibr64-1535759719895274">64</xref>,<xref ref-type="bibr" rid="bibr65-1535759719895274">65</xref></sup> Combinations of therapies can be tested for antiepileptogenic or disease-modifying efficacy in animal models. Another approach is to use extensive literature searches to mine data and create databases of FDA-approved drugs with published efficacy in animal models of epilepsy. Such an effort recently led to a database identifying 173 drugs as potentially appropriate for repurposing.<sup><xref ref-type="bibr" rid="bibr64-1535759719895274">64</xref></sup> Another approach is to take a disease-based screening approach based on a specific assay. For example, a fluorescence-based sodium flux assay for inhibitory activity in a SCN8A R1872Q mutant cell line identified 4 FDA-approved candidate drugs for <italic>SCN8A</italic>-related epilepsy.<sup><xref ref-type="bibr" rid="bibr66-1535759719895274">66</xref></sup></p>
<p>Based on the above considerations, we see as research priorities (1) the identification of mechanisms through which existing FDA-approved drugs affect epileptogenesis and (2) the study of existing FDA-approved drugs in a range of cellular and animal models of epileptogenesis. For example, existing immunomodulatory drugs used for multiple sclerosis may have unexplored antiepileptogenic potential and could be repurposed for epilepsy prevention. Fingolimod, which targets sphingosine-phosphate receptors, was found to have antiepileptogenic and anticonvulsant effects in the intrahippocampal kainic acid murine model.<sup><xref ref-type="bibr" rid="bibr67-1535759719895274">67</xref></sup> Antiepileptogenic and immunomodulatory effects of some statins are another example.<sup><xref ref-type="bibr" rid="bibr68-1535759719895274">68</xref></sup></p>
<p>While animal model studies remain crucial, are there any clinical success stories of FDA-approved drug repurposing for epilepsy? After being used off label to treat patients with epilepsy for nearly 3 decades,<sup><xref ref-type="bibr" rid="bibr69-1535759719895274">69</xref></sup> fenfluramine has recently completed 2 successful phase 3 clinical trials in DS and represents one of the most visible case of drug repurposing in epilepsy.<sup><xref ref-type="bibr" rid="bibr70-1535759719895274">70</xref>,<xref ref-type="bibr" rid="bibr71-1535759719895274">71</xref></sup> Personalized medicine studies in newly described genetic epilepsy syndromes might uncover additional opportunities to use existing drugs. This approach has been tried with the drug quinidine for epilepsy due to gain-of-function in the potassium channel gene KCNT1, although efficacy remains controversial.<sup><xref ref-type="bibr" rid="bibr72-1535759719895274">72</xref></sup> On a cautionary note, while repurposing is a widely pursued strategy for neurological conditions, there are challenges in final translation to humans due to differences in delivery and efficacy when moving, for example, from mouse to human, and due to the realities of paying for phase III clinical trials for medications that either lack new chemical-entity patents and/or are already on the market in generic forms.<sup><xref ref-type="bibr" rid="bibr73-1535759719895274">73</xref></sup></p>
</sec>
<sec id="section9-1535759719895274">
<title>Gene Therapy</title>
<p>Gene therapy involves the induced expression of a therapeutic gene or manipulation of gene expression in a target tissue to alter cellular and tissue and (ideally) disease phenotype. Various investigations have explored the idea of gene therapy for epilepsy to provide an alternative therapeutic option as many forms of epilepsy are difficult to treat with conventional drugs. Viral vector-mediated gene therapy offers the opportunity to target specific mechanisms and cellular populations. These efforts to date have largely focused on preclinical studies, with delivery of various genes into animal models of epilepsy,<sup><xref ref-type="bibr" rid="bibr74-1535759719895274">74</xref><xref ref-type="bibr" rid="bibr75-1535759719895274"></xref><xref ref-type="bibr" rid="bibr76-1535759719895274"></xref>-<xref ref-type="bibr" rid="bibr77-1535759719895274">77</xref></sup> although it was realized long ago that the viral vector approach may also apply to human epileptic tissue.<sup><xref ref-type="bibr" rid="bibr78-1535759719895274">78</xref>,<xref ref-type="bibr" rid="bibr79-1535759719895274">79</xref></sup> Genes for which positive effects from this approach have been reported in animal models of epilepsy include <italic>HSP72</italic>,<sup><xref ref-type="bibr" rid="bibr80-1535759719895274">80</xref></sup> aspartoacylase,<sup><xref ref-type="bibr" rid="bibr81-1535759719895274">81</xref></sup>
<italic>GDNF</italic>,<sup><xref ref-type="bibr" rid="bibr82-1535759719895274">82</xref></sup>
<italic>NPY</italic>,<sup><xref ref-type="bibr" rid="bibr83-1535759719895274">83</xref><xref ref-type="bibr" rid="bibr84-1535759719895274"></xref><xref ref-type="bibr" rid="bibr85-1535759719895274"></xref><xref ref-type="bibr" rid="bibr86-1535759719895274"></xref>-<xref ref-type="bibr" rid="bibr87-1535759719895274">87</xref></sup>
<italic>KCNA1</italic>,<sup><xref ref-type="bibr" rid="bibr88-1535759719895274">88</xref></sup> and adenosine kinase.<sup><xref ref-type="bibr" rid="bibr89-1535759719895274">89</xref></sup> A distinct approach transduces genes with engineered channels, such as an engineered glutamate-gated chloride channel eGluCl<sup><xref ref-type="bibr" rid="bibr90-1535759719895274">90</xref></sup> or an engineered potassium channel.<sup><xref ref-type="bibr" rid="bibr91-1535759719895274">91</xref></sup> Of course, for clinical translation the viruses must accurately target the right populations of human cells.<sup><xref ref-type="bibr" rid="bibr92-1535759719895274">92</xref></sup> A roadmap from gene therapy in animal models to clinical trials has been proposed.<sup><xref ref-type="bibr" rid="bibr93-1535759719895274">93</xref>,<xref ref-type="bibr" rid="bibr94-1535759719895274">94</xref></sup></p>
<p>The strongest rationale for gene therapy approaches is that there is little or nothing in sight for disease prevention or mitigation for certain intractable forms of epilepsy, both for seizures as well as cognitive and other severe comorbidities. For these epilepsy syndromes, we often know the gene as the starting point. There are multiple programs ongoing with the potential to be disease modifying in some forms of epilepsy, which are likely to start clinical trials around 2020, such as an antisense oligonucleotide approach for the treatment of DS (Stoke Therapeutics, Bedford, MA), enzyme-replacement therapy using adeno-associated virus (AAV) vectors for CDKL5 deficiency disorder (Ultragenyx, Novato, CA), and delivering NPY and Y2 receptors through an AAV approach (CombiGene, Lund, Sweden). With the development of better approaches for vector-mediated gene transfer to the central nervous system (CNS), we are likely to see new opportunities for the treatment of various epilepsies. Recent success in single-gene replacement therapy for spinal muscular atrophy type 1<sup><xref ref-type="bibr" rid="bibr95-1535759719895274">95</xref></sup> provides hope in this arena.<sup><xref ref-type="bibr" rid="bibr74-1535759719895274">74</xref></sup></p>
</sec>
</sec>
<sec id="section10-1535759719895274">
<title>Clinical Trials for Epilepsy Prevention</title>
<p>Ultimately the goal of appropriate target identification for antiepileptogenic and/or disease-modifying therapy is translation to clinical trials for epilepsy prevention or modification. Several aspects of this process will need to be assessed for each type of epilepsy:<list list-type="order"><list-item><p><italic>Identification of clinical target populations</italic>: Which populations would be the most appropriate for antiepileptogenic therapy trials? One category would be genetic neurodevelopmental conditions with a latency between clinical recognition of an abnormality and gene diagnosis to epilepsy onset (eg, TSC). Another category would be secondary (acquired) epilepsies with known cause and a delay between the initial event that places an individual at risk for epilepsy and the presentation with epilepsy. Clinical target populations in this category may include patients with PTE, poststroke epilepsy, or postinfectious epilepsy, which is an important cause of epilepsy in the developing world. In these situations, there is a window of opportunity between the inciting stimulus and the development of epilepsy during which one could theoretically intervene to prevent the development of epilepsy. This is in contradistinction to other secondary causes of epilepsy, such as tumor-associated epilepsy, which may present with seizures at the time of diagnosis or not be diagnosed in time for any epilepsy-modifying therapy. In contrast, in the case of PTE, even if the initiating traumatic event is well documented, a challenge may be that the actual development of PTE may occur many years after the initial injury, making enrollment and follow-up for antiepileptogenic efficacy studies difficult.</p></list-item><list-item><p><italic>Identification of high-value therapeutic targets</italic>: Preclinical research in appropriate animal models offers the capability of identifying and validating new therapeutic targets, both through mechanistic understanding and insights from research using repurposed FDA-approved drugs. Human genetics, meanwhile, continues to advance as a resource to identify and validate targets. Emerging computational tools are also being developed to help combine preclinical and clinical data into a framework to identify drug targets<sup><xref ref-type="bibr" rid="bibr96-1535759719895274">96</xref></sup> and also to help predict the safety and efficacy of new targets.<sup><xref ref-type="bibr" rid="bibr97-1535759719895274">97</xref></sup> As new targets are identified and validated, clinical interventional trials can be designed accordingly with either repurposed medications or new drugs.</p></list-item><list-item><p><italic>Stratification with biomarkers</italic>: Stratification of clinical populations with biomarkers that predict epilepsy severity or even the potential for epilepsy to develop (as in assessing the risk of PTE after head trauma) will be important for many reasons, including the notion that trials designed to <italic>prevent</italic> epilepsy after high-risk exposures such as trauma, stroke, or cerebral infection would likely expose people without epilepsy to the effects of antiseizure medications. Careful study of natural history of certain conditions as well as predictive factors that incorporate well-defined and reliable biomarkers of risk of epilepsy or of disease progression will be required before preventive studies can be undertaken. Biomarkers can include susceptibility/risk biomarkers, diagnostic biomarkers, monitoring biomarkers, prognostic/predictive biomarkers, pharmacodynamics/response biomarkers, and safety biomarkers.<sup><xref ref-type="bibr" rid="bibr98-1535759719895274">98</xref></sup> Each category may have distinct types of biomarkers (eg, serological, cerebrospinal fluid, brain tissue, imaging, electrophysiological, and behavioral/cognitive). The path to validation of each biomarker for each epilepsy syndrome will need to continue with high priority for translational epilepsy research. Thus, intermediate biomarkers that predict longer term outcome measures will take on an important role in determining interim outcomes.</p></list-item><list-item><p><italic>Implementation</italic>: After the above considerations are met, there remain logistics and considerations around implementation. With respect to antiepileptogenesis trials, implementation should include the patient/caregiver perspective—what would be decision-making factors for people to enroll in a clinical trial when they have not yet developed epilepsy? Considerations of this sort may be quite different, for example, in 2 different scenarios: the parents of a newborn with TSC at risk of devastating, intractable seizures and disability versus an adult with TBI who may or may not develop seizures. The design and duration of antiepileptogenesis trials also need to be adapted to each of these scenarios based on the known natural history for each epilepsy type.</p></list-item></list></p>
<p>Implementation of antiepileptogenesis trials may differ significantly regarding approach in genetic versus other causes. For genetic syndromes with epilepsy, early diagnosis of course is critical prior to epilepsy onset to enable the enrollment of clinical populations who are at risk, based on electroencephalogram or other biomarkers, but not yet displaying epilepsy. The development of disease-targeted therapeutics for these syndromes will presumably enable preventive treatments and associated clinical trials; examples here would be sodium channel inhibitors for <italic>SCN8A</italic> or <italic>SCN2A</italic> gain-of-function pathogenic variants or mTOR inhibitors for TSC. Some challenges that preventive clinical trials will face in these neurodevelopmental syndromes are the choice of an appropriate time window to delay or prevent epilepsy onset as well as the development and validation of clinical outcome measures for the nonseizure comorbidities. Preclinical genetic models for these syndromes might inform about the temporal window for prevention of epilepsy in these syndromes as well as the potential prevention of comorbidities. Natural history data in patients will also be essential to determine the rate of conversion (ie, development of epilepsy) as well as the duration of the presymptomatic epileptogenic stage to inform trial duration and minimum number of patients for adequate study power.</p>
<p>Distinct causes of secondary epilepsies may warrant support of antiepileptogenesis trials. For example, in some areas of the world, infections of the CNS by neurocysticercosis or other pathogens cause one-third of epilepsies and directly contribute to the higher incidence of epilepsy in resource-poor countries.<sup><xref ref-type="bibr" rid="bibr99-1535759719895274">99</xref></sup> The 2019 World Health Organization report on Epilepsy, A Public Health Imperative highlighted these and other modifiable risk factors as key opportunities to reduce the global burden of epilepsy.<sup><xref ref-type="bibr" rid="bibr100-1535759719895274">100</xref></sup></p>
<p>Antiepileptogenesis trials are currently underway for TSC. A clinical trial for epilepsy prevention using vigabatrin in asymptomatic infants with TSC aiming to lower the risk of developing infantile spasms is currently ongoing (Preventing Epilepsy Using Vigabatrin in Infants with Tuberous Sclerosis Complex, NCT02849457, PREVeNT trial, <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">clinicaltrials.gov</ext-link>). The trial targets a patient population of presymptomatic infants with TSC less than 6 months of age and monitors the developmental impact of epilepsy from birth to 36 months of age. As illustrated in the introductory vignette, the antiepileptogenic or preventive approach is expected to also result in more favorable cognitive, behavioral, and developmental outcomes.</p>
</sec>
<sec id="section11-1535759719895274" sec-type="conclusions">
<title>Conclusion</title>
<p>In summary, successful integrated research programs in antiepileptogenesis will combine<sup><xref ref-type="bibr" rid="bibr101-1535759719895274">101</xref></sup>: (1) animal model studies; (2) development of new animal models (both for genetic epilepsies and acquired epilepsies); (3) development and validation of biomarkers; (4) stratification of treatment groups and outcome evaluations based on validated biomarkers in both animal and human trials; (5) selection of novel creative high-value targets based on preclinical research (such as metabolic, epigenetic, and astrocytic targets reviewed above); (6) screening and repurposing of FDA-approved drugs; and (7) coordination of clinical research strategies to understand the best time window for preventive trials and the ideal patient populations.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="other" id="fn2-1535759719895274">
<p><bold>Authors’ Note:</bold> The opinions expressed in this publication are those of the author(s) and do not necessarily reflect the views of the NIH or the AES.</p>
</fn>
</fn-group>
<ack>
<title>Acknowledgments</title>
<p>We would like to acknowledge the helpful feedback from the Epilepsy Leadership Council and other stewards from the NINDS/AES Epilepsy Research Benchmark Stewards Committee during the formulation of this manuscript.</p>
</ack>
<fn-group>
<fn fn-type="COI-statement" id="fn3-1535759719895274">
<p><bold>Declaration of Conflicting Interests:</bold> The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: AP serves on the Scientific Advisory Board of Tevard and has a spouse/partner that receives a salary from Sanofi Genzyme. WF receives consulting fees from Praxis Precision Medicines, Inc. AM receives consulting fees from F. Hoffman-La Roche, Praxis Precision Medicines, Inc, GW Pharma, Ovid Therapeutics, &amp; Neurelis. D Boison is a cofounder of PrevEp LLC and serves as senior editor for Neuropharmacology.</p>
</fn>
<fn fn-type="financial-disclosure" id="fn4-1535759719895274">
<p><bold>Funding:</bold> The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: The authors gratefully acknowledge research funding from the NIH, NIH R37 NS 031348 (WF), NINDS NS103740 &amp; NS065957 (D Boison).</p>
</fn>
<fn fn-type="other" id="fn5-1535759719895274">
<p><bold>ORCID iD:</bold> Tore Eid <inline-graphic xlink:href="10.1177_1535759719895274-img1.jpg"></inline-graphic>
<ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0001-9217-6393">https://orcid.org/0000-0001-9217-6393</ext-link></p>
<p>Penny A. Dacks <inline-graphic xlink:href="10.1177_1535759719895274-img1.jpg"></inline-graphic>
<ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0003-1149-4192">https://orcid.org/0000-0003-1149-4192</ext-link></p>
<p>Vicky Whittemore <inline-graphic xlink:href="10.1177_1535759719895274-img1.jpg"></inline-graphic>
<ext-link ext-link-type="uri" xlink:href="https://orcid.org/0000-0002-3980-9451">https://orcid.org/0000-0002-3980-9451</ext-link></p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1535759719895274">
<label>1</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Galanopoulou</surname><given-names>AS</given-names></name><name><surname>Wong</surname><given-names>M</given-names></name><name><surname>Binder</surname><given-names>D</given-names></name></person-group>, <etal>et al.</etal>
<article-title>2014 Epilepsy Benchmarks Area II: Prevent Epilepsy and Its Progression</article-title>. <source/>Epilepsy Curr. <year>2016</year>;<volume>16</volume>(<issue>3</issue>):<fpage>187</fpage>–<lpage>191</lpage>.<pub-id pub-id-type="pmid">27330451</pub-id></mixed-citation>
</ref>
<ref id="bibr2-1535759719895274">
<label>2</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Koch</surname><given-names>H</given-names></name><name><surname>Weber</surname><given-names>YG</given-names></name></person-group>
<article-title>The glucose transporter type 1 (Glut1) syndromes</article-title>. <source/>Epilepsy Behav. <year>2019</year>;<volume>91</volume>:<fpage>90</fpage>–<lpage>93</lpage>.<pub-id pub-id-type="pmid">30076047</pub-id></mixed-citation>
</ref>
<ref id="bibr3-1535759719895274">
<label>3</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Boison</surname><given-names>D</given-names></name><name><surname>Steinhauser</surname><given-names>C</given-names></name></person-group>
<article-title>Epilepsy and astrocyte energy metabolism</article-title>. <source/>Glia. <year>2018</year>;<volume>66</volume>(<issue>6</issue>):<fpage>1235</fpage>–<lpage>1243</lpage>.<pub-id pub-id-type="pmid">29044647</pub-id></mixed-citation>
</ref>
<ref id="bibr4-1535759719895274">
<label>4</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lusardi</surname><given-names>TA</given-names></name><name><surname>Akula</surname><given-names>KK</given-names></name><name><surname>Coffman</surname><given-names>SQ</given-names></name><name><surname>Ruskin</surname><given-names>DN</given-names></name><name><surname>Masino</surname><given-names>SA</given-names></name><name><surname>Boison</surname><given-names>D</given-names></name></person-group>
<article-title>Ketogenic diet prevents epileptogenesis and disease progression in adult mice and rats</article-title>. <source/>Neuropharmacology. <year>2015</year>;<volume>99</volume>:<fpage>500</fpage>–<lpage>509</lpage>.<pub-id pub-id-type="pmid">26256422</pub-id></mixed-citation>
</ref>
<ref id="bibr5-1535759719895274">
<label>5</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kobow</surname><given-names>K</given-names></name><name><surname>Kaspi</surname><given-names>A</given-names></name><name><surname>Harikrishnan</surname><given-names>KN</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Deep sequencing reveals increased DNA methylation in chronic rat epilepsy</article-title>. <source/>Acta neuropathologica. <year>2013</year>;<volume>126</volume>(<issue>5</issue>):<fpage>741</fpage>–<lpage>756</lpage>.<pub-id pub-id-type="pmid">24005891</pub-id></mixed-citation>
</ref>
<ref id="bibr6-1535759719895274">
<label>6</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Simeone</surname><given-names>KA</given-names></name><name><surname>Matthews</surname><given-names>SA</given-names></name><name><surname>Rho</surname><given-names>JM</given-names></name><name><surname>Simeone</surname><given-names>TA</given-names></name></person-group>
<article-title>Ketogenic diet treatment increases longevity in Kcna1-null mice, a model of sudden unexpected death in epilepsy</article-title>. <source/>Epilepsia. <year>2016</year>;<volume>57</volume>(<issue>8</issue>):<fpage>e178</fpage>–<lpage>182</lpage>.<pub-id pub-id-type="pmid">27346881</pub-id></mixed-citation>
</ref>
<ref id="bibr7-1535759719895274">
<label>7</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Patel</surname><given-names>M</given-names></name></person-group>
<article-title>A metabolic paradigm for epilepsy</article-title>. <source/>Epilepsy Curr. <year>2018</year>;<volume>18</volume>(<issue>5</issue>):<fpage>318</fpage>–<lpage>322</lpage>.<pub-id pub-id-type="pmid">30464734</pub-id></mixed-citation>
</ref>
<ref id="bibr8-1535759719895274">
<label>8</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lutas</surname><given-names>A</given-names></name><name><surname>Yellen</surname><given-names>G</given-names></name></person-group>
<article-title>The ketogenic diet: metabolic influences on brain excitability and epilepsy</article-title>. <source/>Trends Neurosci. <year>2013</year>;<volume>36</volume>(<issue>1</issue>):<fpage>32</fpage>–<lpage>40</lpage>.<pub-id pub-id-type="pmid">23228828</pub-id></mixed-citation>
</ref>
<ref id="bibr9-1535759719895274">
<label>9</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Augustin</surname><given-names>K</given-names></name><name><surname>Khabbush</surname><given-names>A</given-names></name><name><surname>Williams</surname><given-names>S</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Mechanisms of action for the medium-chain triglyceride ketogenic diet in neurological and metabolic disorders</article-title>. <source/>Lancet Neurol. <year>2018</year>;<volume>17</volume>(<issue>1</issue>):<fpage>84</fpage>–<lpage>93</lpage>.<pub-id pub-id-type="pmid">29263011</pub-id></mixed-citation>
</ref>
<ref id="bibr10-1535759719895274">
<label>10</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>McDonald</surname><given-names>TS</given-names></name><name><surname>Tan</surname><given-names>KN</given-names></name><name><surname>Hodson</surname><given-names>MP</given-names></name><name><surname>Borges</surname><given-names>K</given-names></name></person-group>
<article-title>Alterations of hippocampal glucose metabolism by even versus uneven medium chain triglycerides</article-title>. <source/>J Cereb Blood Flow Metab. <year>2014</year>;<fpage>153</fpage>–<lpage>160</lpage>.<pub-id pub-id-type="pmid">24169853</pub-id></mixed-citation>
</ref>
<ref id="bibr11-1535759719895274">
<label>11</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kim</surname><given-names>DY</given-names></name><name><surname>Simeone</surname><given-names>KA</given-names></name><name><surname>Simeone</surname><given-names>TA</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Ketone bodies mediate antiseizure effects through mitochondrial permeability transition</article-title>. <source/>Ann Neurol. <year>2015</year>;<volume>78</volume>(<issue>1</issue>):<fpage>77</fpage>–<lpage>87</lpage>.<pub-id pub-id-type="pmid">25899847</pub-id></mixed-citation>
</ref>
<ref id="bibr12-1535759719895274">
<label>12</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Chang</surname><given-names>P</given-names></name><name><surname>Augustin</surname><given-names>K</given-names></name><name><surname>Boddum</surname><given-names>K</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Seizure control by decanoic acid through direct AMPA receptor inhibition</article-title>. <source/>Brain. <year>2016</year>;<volume>139</volume>(<issue>Pt 2</issue>):<fpage>431</fpage>–<lpage>443</lpage>.<pub-id pub-id-type="pmid">26608744</pub-id></mixed-citation>
</ref>
<ref id="bibr13-1535759719895274">
<label>13</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Auvin</surname><given-names>S</given-names></name></person-group>
<article-title>Non-pharmacological medical treatment in pediatric epilepsies</article-title>. <source/>Rev Neurol (Paris). <year>2016</year>;<volume>172</volume>(<issue>3</issue>):<fpage>182</fpage>–<lpage>185</lpage>.<pub-id pub-id-type="pmid">26993568</pub-id></mixed-citation>
</ref>
<ref id="bibr14-1535759719895274">
<label>14</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ibhazehiebo</surname><given-names>K</given-names></name><name><surname>Gavrilovici</surname><given-names>C</given-names></name><name><surname>de la Hoz</surname><given-names>CL</given-names></name></person-group>, <etal>et al.</etal>
<article-title>A novel metabolism-based phenotypic drug discovery platform in zebrafish uncovers HDACs 1 and 3 as a potential combined anti-seizure drug target</article-title>. <source/>Brain. <year>2018</year>;<fpage>744</fpage>–<lpage>761</lpage>.<pub-id pub-id-type="pmid">29373639</pub-id></mixed-citation>
</ref>
<ref id="bibr15-1535759719895274">
<label>15</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kumar</surname><given-names>MG</given-names></name><name><surname>Rowley</surname><given-names>S</given-names></name><name><surname>Fulton</surname><given-names>R</given-names></name><name><surname>Dinday</surname><given-names>MT</given-names></name><name><surname>Baraban</surname><given-names>SC</given-names></name><name><surname>Patel</surname><given-names>M</given-names></name></person-group>
<article-title>Altered glycolysis and mitochondrial respiration in a zebrafish model of dravet syndrome</article-title>. <source/>eNeuro. <year>2016</year>;<volume>3</volume>(<issue>2</issue>):<fpage>8</fpage>–<lpage>16</lpage>.</mixed-citation>
</ref>
<ref id="bibr16-1535759719895274">
<label>16</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sada</surname><given-names>N</given-names></name><name><surname>Lee</surname><given-names>S</given-names></name><name><surname>Katsu</surname><given-names>T</given-names></name><name><surname>Otsuki</surname><given-names>T</given-names></name><name><surname>Inoue</surname><given-names>T</given-names></name></person-group>
<article-title>Epilepsy treatment. targeting LDH enzymes with a stiripentol analog to treat epilepsy</article-title>. <source/>Science. <year>2015</year>;<volume>347</volume>(<issue>6228</issue>):<fpage>1362</fpage>–<lpage>1367</lpage>.<pub-id pub-id-type="pmid">25792327</pub-id></mixed-citation>
</ref>
<ref id="bibr17-1535759719895274">
<label>17</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Koenig</surname><given-names>JB</given-names></name><name><surname>Dulla</surname><given-names>CG</given-names></name></person-group>
<article-title>Dysregulated glucose metabolism as a therapeutic target to reduce post-traumatic epilepsy</article-title>. <source/>Front Cell Neurosci. <year>2018</year>;<volume>12</volume>:<fpage>350</fpage>.<pub-id pub-id-type="pmid">30459556</pub-id></mixed-citation>
</ref>
<ref id="bibr18-1535759719895274">
<label>18</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Masino</surname><given-names>SA</given-names></name><name><surname>Rho</surname><given-names>JM</given-names></name></person-group>
<article-title>Metabolism and epilepsy: ketogenic diets as a homeostatic link</article-title>. <source/>Brain Res. <year>2019</year>;<volume>1703</volume>:<fpage>26</fpage>–<lpage>30</lpage>.<pub-id pub-id-type="pmid">29883626</pub-id></mixed-citation>
</ref>
<ref id="bibr19-1535759719895274">
<label>19</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Newell</surname><given-names>C</given-names></name><name><surname>Bomhof</surname><given-names>MR</given-names></name><name><surname>Reimer</surname><given-names>RA</given-names></name><name><surname>Hittel</surname><given-names>DS</given-names></name><name><surname>Rho</surname><given-names>JM</given-names></name><name><surname>Shearer</surname><given-names>J</given-names></name></person-group>
<article-title>Ketogenic diet modifies the gut microbiota in a murine model of autism spectrum disorder</article-title>. <source/>Mole Autism. <year>2016</year>;<volume>7</volume>(<issue>1</issue>):<fpage>37</fpage>.</mixed-citation>
</ref>
<ref id="bibr20-1535759719895274">
<label>20</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Peng</surname><given-names>A</given-names></name><name><surname>Qiu</surname><given-names>X</given-names></name><name><surname>Lai</surname><given-names>W</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Altered composition of the gut microbiome in patients with drug-resistant epilepsy</article-title>. <source/>Epilepsy Res. <year>2018</year>;<volume>147</volume>:<fpage>102</fpage>–<lpage>107</lpage>.<pub-id pub-id-type="pmid">30291996</pub-id></mixed-citation>
</ref>
<ref id="bibr21-1535759719895274">
<label>21</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Yu</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name></person-group>
<article-title>Altered gut microbiome composition in children with refractory epilepsy after ketogenic diet</article-title>. <source/>Epilepsy Res. <year>2018</year>;<volume>145</volume>:<fpage>163</fpage>–<lpage>168</lpage>.<pub-id pub-id-type="pmid">30007242</pub-id></mixed-citation>
</ref>
<ref id="bibr22-1535759719895274">
<label>22</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dahlin</surname><given-names>M</given-names></name><name><surname>Prast-Nielsen</surname><given-names>S</given-names></name></person-group>
<article-title>The gut microbiome and epilepsy</article-title>. <source/>EbioMed. <year>2019</year>;<volume>44</volume>:<fpage>741</fpage>–<lpage>746</lpage>.</mixed-citation>
</ref>
<ref id="bibr23-1535759719895274">
<label>23</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Basu</surname><given-names>T</given-names></name><name><surname>O’Riordan</surname><given-names>KJ</given-names></name><name><surname>Schoenike</surname><given-names>BA</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Histone deacetylase inhibitors restore normal hippocampal synaptic plasticity and seizure threshold in a mouse model of tuberous sclerosis complex</article-title>. <source/>Sci Rep. <year>2019</year>;<volume>9</volume>(<issue>1</issue>):<fpage>5266</fpage>.<pub-id pub-id-type="pmid">30918308</pub-id></mixed-citation>
</ref>
<ref id="bibr24-1535759719895274">
<label>24</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Reddy</surname><given-names>SD</given-names></name><name><surname>Clossen</surname><given-names>BL</given-names></name><name><surname>Reddy</surname><given-names>DS</given-names></name></person-group>
<article-title>Epigenetic histone deacetylation inhibition prevents the development and persistence of temporal lobe epilepsy</article-title>. <source/>J Pharmacol Exp Ther. <year>2018</year>;<volume>364</volume>(<issue>1</issue>):<fpage>97</fpage>–<lpage>109</lpage>.<pub-id pub-id-type="pmid">29101217</pub-id></mixed-citation>
</ref>
<ref id="bibr25-1535759719895274">
<label>25</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ryley Parrish</surname><given-names>R</given-names></name><name><surname>Albertson</surname><given-names>AJ</given-names></name><name><surname>Buckingham</surname><given-names>SC</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Status epilepticus triggers early and late alterations in brain-derived neurotrophic factor and NMDA glutamate receptor Grin2b DNA methylation levels in the hippocampus</article-title>. <source/>Neurosci. <year>2013</year>;<volume>248</volume>:<fpage>602</fpage>–<lpage>619</lpage>.</mixed-citation>
</ref>
<ref id="bibr26-1535759719895274">
<label>26</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jagirdar</surname><given-names>R</given-names></name><name><surname>Drexel</surname><given-names>M</given-names></name><name><surname>Bukovac</surname><given-names>A</given-names></name><name><surname>Tasan</surname><given-names>RO</given-names></name><name><surname>Sperk</surname><given-names>G</given-names></name></person-group>
<article-title>Expression of class II histone deacetylases in two mouse models of temporal lobe epilepsy</article-title>. <source/>J Neurochem. <year>2016</year>;<volume>136</volume>(<issue>4</issue>):<fpage>717</fpage>–<lpage>730</lpage>.<pub-id pub-id-type="pmid">26603269</pub-id></mixed-citation>
</ref>
<ref id="bibr27-1535759719895274">
<label>27</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jagirdar</surname><given-names>R</given-names></name><name><surname>Drexel</surname><given-names>M</given-names></name><name><surname>Kirchmair</surname><given-names>E</given-names></name><name><surname>Tasan</surname><given-names>RO</given-names></name><name><surname>Sperk</surname><given-names>G</given-names></name></person-group>
<article-title>Rapid changes in expression of class I and IV histone deacetylases during epileptogenesis in mouse models of temporal lobe epilepsy</article-title>. <source/>Expe Neurol. <year>2015</year>;<volume>273</volume>:<fpage>92</fpage>–<lpage>104</lpage>.</mixed-citation>
</ref>
<ref id="bibr28-1535759719895274">
<label>28</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Dixit</surname><given-names>AB</given-names></name><name><surname>Sharma</surname><given-names>D</given-names></name><name><surname>Tripathi</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Genome-wide DNA methylation and RNAseq analyses identify aberrant signalling pathways in focal cortical dysplasia (FCD) Type II</article-title>. <source/>Sci Rep. <year>2018</year>;<volume>8</volume>(<issue>1</issue>):<fpage>17976</fpage>.<pub-id pub-id-type="pmid">30568293</pub-id></mixed-citation>
</ref>
<ref id="bibr29-1535759719895274">
<label>29</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Miller-Delaney</surname><given-names>SF</given-names></name><name><surname>Bryan</surname><given-names>K</given-names></name><name><surname>Das</surname><given-names>S</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Differential DNA methylation profiles of coding and non-coding genes define hippocampal sclerosis in human temporal lobe epilepsy</article-title>. <source/>Brain J Neurol. <year>2015</year>;<volume>138</volume>(<issue>Pt 3</issue>):<fpage>616</fpage>–<lpage>631</lpage>.</mixed-citation>
</ref>
<ref id="bibr30-1535759719895274">
<label>30</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Increased expression of DNA methyltransferase 1 and 3a in human temporal lobe epilepsy</article-title>. <source/>J Mol Neurosci. <year>2012</year>;<volume>46</volume>(<issue>2</issue>):<fpage>420</fpage>–<lpage>426</lpage>.<pub-id pub-id-type="pmid">21826395</pub-id></mixed-citation>
</ref>
<ref id="bibr31-1535759719895274">
<label>31</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Williams-Karnesky</surname><given-names>RL</given-names></name><name><surname>Sandau</surname><given-names>US</given-names></name><name><surname>Lusardi</surname><given-names>TA</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Epigenetic changes induced by adenosine augmentation therapy prevent epileptogenesis</article-title>. <source/>J Clin Invest. <year>2013</year>;<volume>123</volume>(<issue>8</issue>):<fpage>3552</fpage>–<lpage>3563</lpage>.<pub-id pub-id-type="pmid">23863710</pub-id></mixed-citation>
</ref>
<ref id="bibr32-1535759719895274">
<label>32</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sandau</surname><given-names>US</given-names></name><name><surname>Yahya</surname><given-names>M</given-names></name><name><surname>Bigej</surname><given-names>R</given-names></name><name><surname>Friedman</surname><given-names>JL</given-names></name><name><surname>Saleumvong</surname><given-names>B</given-names></name><name><surname>Boison</surname><given-names>D</given-names></name></person-group>
<article-title>Transient use of a systemic adenosine kinase inhibitor attenuates epilepsy development in mice</article-title>. <source/>Epilepsia. <year>2019</year>;<volume>60</volume>(<issue>4</issue>):<fpage>615</fpage>–<lpage>625</lpage>.<pub-id pub-id-type="pmid">30815855</pub-id></mixed-citation>
</ref>
<ref id="bibr33-1535759719895274">
<label>33</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Gottlicher</surname><given-names>M</given-names></name><name><surname>Minucci</surname><given-names>S</given-names></name><name><surname>Zhu</surname><given-names>P</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells</article-title>. <source/>EMBO J. <year>2001</year>;<volume>20</volume>(<issue>24</issue>):<fpage>6969</fpage>–<lpage>6978</lpage>.<pub-id pub-id-type="pmid">11742974</pub-id></mixed-citation>
</ref>
<ref id="bibr34-1535759719895274">
<label>34</label>
<mixed-citation publication-type="book">
<person-group person-group-type="author"><name><surname>Hubbard</surname><given-names>JA</given-names></name><name><surname>Binder</surname><given-names>DK</given-names></name></person-group>
<source/>Astrocytes and Epilepsy. <publisher-loc>Amsterdam, the Netherlands</publisher-loc>: <publisher-name>Academic Press</publisher-name>; <year>2016</year>.</mixed-citation>
</ref>
<ref id="bibr35-1535759719895274">
<label>35</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Tian</surname><given-names>GF</given-names></name><name><surname>Azmi</surname><given-names>H</given-names></name><name><surname>Takano</surname><given-names>T</given-names></name></person-group>, <etal>et al.</etal>
<article-title>An astrocytic basis of epilepsy</article-title>. <source/>Nat Med. <year>2005</year>;<volume>11</volume>:<fpage>973</fpage>–<lpage>981</lpage>.<pub-id pub-id-type="pmid">16116433</pub-id></mixed-citation>
</ref>
<ref id="bibr36-1535759719895274">
<label>36</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Binder</surname><given-names>DK</given-names></name></person-group>
<article-title>Astrocytes: stars of the sacred disease</article-title>. <source/>Epilepsy Curr. <year>2018</year>;<volume>18</volume>(<issue>3</issue>):<fpage>172</fpage>–<lpage>179</lpage>.<pub-id pub-id-type="pmid">29950942</pub-id></mixed-citation>
</ref>
<ref id="bibr37-1535759719895274">
<label>37</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Uhlmann</surname><given-names>EJ</given-names></name><name><surname>Wong</surname><given-names>M</given-names></name><name><surname>Baldwin</surname><given-names>RL</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Astrocyte-specific TSC1 conditional knockout mice exhibit abnormal neuronal organization and seizures</article-title>. <source/>Ann Neurol. <year>2002</year>;<volume>52</volume>(<issue>3</issue>):<fpage>285</fpage>–<lpage>296</lpage>.<pub-id pub-id-type="pmid">12205640</pub-id></mixed-citation>
</ref>
<ref id="bibr38-1535759719895274">
<label>38</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wong</surname><given-names>M</given-names></name><name><surname>Ess</surname><given-names>KC</given-names></name><name><surname>Uhlmann</surname><given-names>EJ</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Impaired glial glutamate transport in a mouse tuberous sclerosis epilepsy model</article-title>. <source/>Ann Neurol. <year>2003</year>;<volume>54</volume>(<issue>2</issue>):<fpage>251</fpage>–<lpage>256</lpage>.<pub-id pub-id-type="pmid">12891680</pub-id></mixed-citation>
</ref>
<ref id="bibr39-1535759719895274">
<label>39</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Jansen</surname><given-names>LA</given-names></name><name><surname>Uhlmann</surname><given-names>EJ</given-names></name><name><surname>Crino</surname><given-names>PB</given-names></name><name><surname>Gutmann</surname><given-names>DH</given-names></name><name><surname>Wong</surname><given-names>M</given-names></name></person-group>
<article-title>Epileptogenesis and reduced inward rectifier potassium current in tuberous sclerosis complex-1-deficient astrocytes</article-title>. <source/>Epilepsia. <year>2005</year>;<volume>46</volume>(<issue>12</issue>):<fpage>1871</fpage>–<lpage>1880</lpage>.<pub-id pub-id-type="pmid">16393152</pub-id></mixed-citation>
</ref>
<ref id="bibr40-1535759719895274">
<label>40</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Zou</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>B</given-names></name><name><surname>Gutmann</surname><given-names>DH</given-names></name><name><surname>Wong</surname><given-names>M</given-names></name></person-group>
<article-title>Postnatal reduction of tuberous sclerosis complex 1 expression in astrocytes and neurons causes seizures in an age-dependent manner</article-title>. <source/>Epilepsia. <year>2017</year>;<volume>58</volume>(<issue>12</issue>):<fpage>2053</fpage>–<lpage>2063</lpage>.<pub-id pub-id-type="pmid">29023667</pub-id></mixed-citation>
</ref>
<ref id="bibr41-1535759719895274">
<label>41</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Annegers</surname><given-names>JF</given-names></name><name><surname>Hauser</surname><given-names>WA</given-names></name><name><surname>Coan</surname><given-names>SP</given-names></name><name><surname>Rocca</surname><given-names>WA</given-names></name></person-group>
<article-title>A population-based study of seizures after traumatic brain injuries</article-title>. <source/>N Engl J Med. <year>1998</year>;<volume>338</volume>(<issue>1</issue>):<fpage>20</fpage>–<lpage>24</lpage>.<pub-id pub-id-type="pmid">9414327</pub-id></mixed-citation>
</ref>
<ref id="bibr42-1535759719895274">
<label>42</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Caveness</surname><given-names>WF</given-names></name><name><surname>Meirowsky</surname><given-names>AM</given-names></name><name><surname>Rish</surname><given-names>BL</given-names></name></person-group>, <etal>et al.</etal>
<article-title>The nature of posttraumatic epilepsy</article-title>. <source/>J Neurosurg. <year>1979</year>;<volume>50</volume>(<issue>5</issue>):<fpage>545</fpage>–<lpage>553</lpage>.<pub-id pub-id-type="pmid">107289</pub-id></mixed-citation>
</ref>
<ref id="bibr43-1535759719895274">
<label>43</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Temkin</surname><given-names>NR</given-names></name><name><surname>Dikmen</surname><given-names>SS</given-names></name><name><surname>Wilensky</surname><given-names>AJ</given-names></name><name><surname>Keihm</surname><given-names>J</given-names></name><name><surname>Chabal</surname><given-names>S</given-names></name><name><surname>Winn</surname><given-names>HR</given-names></name></person-group>
<article-title>A randomized, double-blind study of phenytoin for the prevention of post-traumatic seizures</article-title>. <source/>N Engl J Med. <year>1990</year>;<volume>323</volume>(<issue>8</issue>):<fpage>497</fpage>–<lpage>502</lpage>.<pub-id pub-id-type="pmid">2115976</pub-id></mixed-citation>
</ref>
<ref id="bibr44-1535759719895274">
<label>44</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Temkin</surname><given-names>NR</given-names></name><name><surname>Dikmen</surname><given-names>SS</given-names></name><name><surname>Anderson</surname><given-names>GD</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Valproate therapy for prevention of posttraumatic seizures: a randomized trial</article-title>. <source/>J Neurosurg. <year>1999</year>;<volume>91</volume>(<issue>4</issue>):<fpage>593</fpage>–<lpage>600</lpage>.<pub-id pub-id-type="pmid">10507380</pub-id></mixed-citation>
</ref>
<ref id="bibr45-1535759719895274">
<label>45</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>D’Ambrosio</surname><given-names>R</given-names></name><name><surname>Perucca</surname><given-names>E</given-names></name></person-group>
<article-title>Epilepsy after head injury</article-title>. <source/>Curr Opin Neurol. <year>2004</year>;<volume>17</volume>(<issue>6</issue>):<fpage>731</fpage>–<lpage>735</lpage>.<pub-id pub-id-type="pmid">15542983</pub-id></mixed-citation>
</ref>
<ref id="bibr46-1535759719895274">
<label>46</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lowenstein</surname><given-names>DH</given-names></name><name><surname>Thomas</surname><given-names>MJ</given-names></name><name><surname>Smith</surname><given-names>DH</given-names></name><name><surname>McIntosh</surname><given-names>TK</given-names></name></person-group>
<article-title>Selective vulnerability of dentate hilar neurons following traumatic brain injury: a potential mechanistic link between head trauma and disorders of the hippocampus</article-title>. <source/>J Neurophysiol. <year>1992</year>;<volume>12</volume>(<issue>12</issue>):<fpage>4846</fpage>–<lpage>4853</lpage>.</mixed-citation>
</ref>
<ref id="bibr47-1535759719895274">
<label>47</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Golarai</surname><given-names>G</given-names></name><name><surname>Greenwood</surname><given-names>AC</given-names></name><name><surname>Feeney</surname><given-names>DM</given-names></name><name><surname>Connor</surname><given-names>JA</given-names></name></person-group>
<article-title>Physiological and structural evidence for hippocampal involvement in persistent seizure susceptibility after traumatic brain injury</article-title>. <source/>J Neurophysiol. <year>2001</year>;<volume>21</volume>(<issue>21</issue>):<fpage>8523</fpage>–<lpage>8537</lpage>.</mixed-citation>
</ref>
<ref id="bibr48-1535759719895274">
<label>48</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Santhakumar</surname><given-names>V</given-names></name><name><surname>Ratzliff</surname><given-names>AD</given-names></name><name><surname>Jeng</surname><given-names>J</given-names></name><name><surname>Toth</surname><given-names>Z</given-names></name><name><surname>Soltesz</surname><given-names>I</given-names></name></person-group>
<article-title>Long-term hyperexcitability in the hippocampus after experimental head trauma</article-title>. <source/>Ann Neurol. <year>2001</year>;<volume>50</volume>(<issue>6</issue>):<fpage>708</fpage>–<lpage>717</lpage>.<pub-id pub-id-type="pmid">11761468</pub-id></mixed-citation>
</ref>
<ref id="bibr49-1535759719895274">
<label>49</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hunt</surname><given-names>RF</given-names></name><name><surname>Scheff</surname><given-names>SW</given-names></name><name><surname>Smith</surname><given-names>BN</given-names></name></person-group>
<article-title>Posttraumatic epilepsy after controlled cortical impact injury in mice</article-title>. <source/>Exp Neurol. <year>2009</year>;<volume>215</volume>(<issue>2</issue>):<fpage>243</fpage>–<lpage>252</lpage>.<pub-id pub-id-type="pmid">19013458</pub-id></mixed-citation>
</ref>
<ref id="bibr50-1535759719895274">
<label>50</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Hunt</surname><given-names>RF</given-names></name><name><surname>Scheff</surname><given-names>SW</given-names></name><name><surname>Smith</surname><given-names>BN</given-names></name></person-group>
<article-title>Regionally localized recurrent excitation in the dentate gyrus of a cortical contusion model of posttraumatic epilepsy</article-title>. <source/>J Neurophysiol. <year>2010</year>;<volume>103</volume>(<issue>3</issue>):<fpage>1490</fpage>–<lpage>1500</lpage>.<pub-id pub-id-type="pmid">20089815</pub-id></mixed-citation>
</ref>
<ref id="bibr51-1535759719895274">
<label>51</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Butler</surname><given-names>CR</given-names></name><name><surname>Boychuk</surname><given-names>JA</given-names></name><name><surname>Smith</surname><given-names>BN</given-names></name></person-group>
<article-title>Effects of rapamycin treatment on neurogenesis and synaptic reorganization in the dentate gyrus after controlled cortical impact injury in mice</article-title>. <source/>Front Syst Neurosci. <year>2015</year>;<volume>9</volume>:<fpage>163</fpage>.<pub-id pub-id-type="pmid">26640431</pub-id></mixed-citation>
</ref>
<ref id="bibr52-1535759719895274">
<label>52</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Butler</surname><given-names>CR</given-names></name><name><surname>Boychuk</surname><given-names>JA</given-names></name><name><surname>Smith</surname><given-names>BN</given-names></name></person-group>
<article-title>Brain injury-induced synaptic reorganization in hilar inhibitory neurons is differentially suppressed by rapamycin</article-title>. <source/>Eneur. <year>2017</year>;<volume>4</volume>(<issue>5</issue>):<comment>ENEURO.0134-17.2017</comment>.</mixed-citation>
</ref>
<ref id="bibr53-1535759719895274">
<label>53</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Boychuk</surname><given-names>JA</given-names></name><name><surname>Butler</surname><given-names>CR</given-names></name><name><surname>Halmos</surname><given-names>KC</given-names></name><name><surname>Smith</surname><given-names>BN</given-names></name></person-group>
<article-title>Enduring changes in tonic GABAA receptor signaling in dentate granule cells after controlled cortical impact brain injury in mice</article-title>. <source/>Exp Neurol. <year>2016</year>;<volume>277</volume>:<fpage>178</fpage>–<lpage>189</lpage>.<pub-id pub-id-type="pmid">26772635</pub-id></mixed-citation>
</ref>
<ref id="bibr54-1535759719895274">
<label>54</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>D’Ambrosio</surname><given-names>R</given-names></name><name><surname>Maris</surname><given-names>DO</given-names></name><name><surname>Grady</surname><given-names>MS</given-names></name><name><surname>Winn</surname><given-names>HR</given-names></name><name><surname>Janigro</surname><given-names>D</given-names></name></person-group>
<article-title>Impaired K<sup>+</sup> homeostasis and altered electrophysiological properties of post-traumatic hippocampal glia</article-title>. <source/>J Neurosci. <year>1999</year>;<volume>19</volume>(<issue>18</issue>):<fpage>8152</fpage>–<lpage>8162</lpage>.<pub-id pub-id-type="pmid">10479715</pub-id></mixed-citation>
</ref>
<ref id="bibr55-1535759719895274">
<label>55</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Samuelsson</surname><given-names>C</given-names></name><name><surname>Kumlien</surname><given-names>E</given-names></name><name><surname>Flink</surname><given-names>R</given-names></name><name><surname>Lindholm</surname><given-names>D</given-names></name><name><surname>Ronne-Engstrom</surname><given-names>E</given-names></name></person-group>
<article-title>Decreased cortical levels of astrocytic glutamate transport protein GLT-1 in a rat model of posttraumatic epilepsy</article-title>. <source/>Neurosci Lett. <year>2000</year>;<volume>289</volume>(<issue>3</issue>):<fpage>185</fpage>–<lpage>188</lpage>.<pub-id pub-id-type="pmid">10961660</pub-id></mixed-citation>
</ref>
<ref id="bibr56-1535759719895274">
<label>56</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Klein</surname><given-names>P</given-names></name><name><surname>Dingledine</surname><given-names>R</given-names></name><name><surname>Aronica</surname><given-names>E</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Commonalities in epileptogenic processes from different acute brain insults: do they translate?</article-title>
<source/>Epilepsia. <year>2018</year>;<volume>59</volume>(<issue>1</issue>):<fpage>37</fpage>–<lpage>66</lpage>.<pub-id pub-id-type="pmid">29247482</pub-id></mixed-citation>
</ref>
<ref id="bibr57-1535759719895274">
<label>57</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bugay</surname><given-names>V</given-names></name><name><surname>Bozdemir</surname><given-names>E</given-names></name><name><surname>Vigil</surname><given-names>FA</given-names></name></person-group>, <etal>et al.</etal>
<article-title>A mouse model of repetitive blast traumatic brain injury reveals post-trauma seizures and increased neuronal excitability</article-title>. <source/>J Neurotrauma. <year>2019</year>
<comment>doi: 10.1089/neu.2018.6333.</comment>
</mixed-citation>
</ref>
<ref id="bibr58-1535759719895274">
<label>58</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shandra</surname><given-names>O</given-names></name><name><surname>Winemiller</surname><given-names>AR</given-names></name><name><surname>Heithoff</surname><given-names>BP</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Repetitive diffuse mild traumatic brain injury causes an atypical astrocyte response and spontaneous recurrent seizures</article-title>. <source/>J Neurosci. <year>2019</year>;<volume>39</volume>(<issue>10</issue>):<fpage>1944</fpage>–<lpage>1963</lpage>.<pub-id pub-id-type="pmid">30665946</pub-id></mixed-citation>
</ref>
<ref id="bibr59-1535759719895274">
<label>59</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Seiffert</surname><given-names>E</given-names></name><name><surname>Dreier</surname><given-names>JP</given-names></name><name><surname>Ivens</surname><given-names>S</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Lasting blood-brain barrier disruption induces epileptic focus in the rat somatosensory cortex</article-title>. <source/>J Neurosci. <year>2004</year>;<volume>24</volume>(<issue>36</issue>):<fpage>7829</fpage>–<lpage>7836</lpage>.<pub-id pub-id-type="pmid">15356194</pub-id></mixed-citation>
</ref>
<ref id="bibr60-1535759719895274">
<label>60</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Weissberg</surname><given-names>I</given-names></name><name><surname>Wood</surname><given-names>L</given-names></name><name><surname>Kamintsky</surname><given-names>L</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Albumin induces excitatory synaptogenesis through astrocytic TGF-beta/ALK5 signaling in a model of acquired epilepsy following blood-brain barrier dysfunction</article-title>. <source/>Neurobiol Dis. <year>2015</year>;<volume>78</volume>:<fpage>115</fpage>–<lpage>125</lpage>.<pub-id pub-id-type="pmid">25836421</pub-id></mixed-citation>
</ref>
<ref id="bibr61-1535759719895274">
<label>61</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bar-Klein</surname><given-names>G</given-names></name><name><surname>Cacheaux</surname><given-names>LP</given-names></name><name><surname>Kamintsky</surname><given-names>L</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Losartan prevents acquired epilepsy via TGF-beta signaling suppression</article-title>. <source/>Ann Neurol. <year>2014</year>;<volume>75</volume>(<issue>6</issue>):<fpage>864</fpage>–<lpage>875</lpage>.<pub-id pub-id-type="pmid">24659129</pub-id></mixed-citation>
</ref>
<ref id="bibr62-1535759719895274">
<label>62</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Friedman</surname><given-names>A</given-names></name><name><surname>Bar-Klein</surname><given-names>G</given-names></name><name><surname>Serlin</surname><given-names>Y</given-names></name><name><surname>Parmet</surname><given-names>Y</given-names></name><name><surname>Heinemann</surname><given-names>U</given-names></name><name><surname>Kaufer</surname><given-names>D</given-names></name></person-group>
<article-title>Should losartan be administered following brain injury?</article-title>
<source/>Expert Rev Neurother. <year>2014</year>;<volume>14</volume>(<issue>12</issue>):<fpage>1365</fpage>–<lpage>1375</lpage>.<pub-id pub-id-type="pmid">25346269</pub-id></mixed-citation>
</ref>
<ref id="bibr63-1535759719895274">
<label>63</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Bar-Klein</surname><given-names>G</given-names></name><name><surname>Lublinsky</surname><given-names>S</given-names></name><name><surname>Kamintsky</surname><given-names>L</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Imaging blood-brain barrier dysfunction as a biomarker for epileptogenesis</article-title>. <source/>Brain J Neurol. <year>2017</year>;<volume>140</volume>(<issue>6</issue>):<fpage>1692</fpage>–<lpage>1705</lpage>.</mixed-citation>
</ref>
<ref id="bibr64-1535759719895274">
<label>64</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Sivapalarajah</surname><given-names>S</given-names></name><name><surname>Krishnakumar</surname><given-names>M</given-names></name><name><surname>Bickerstaffe</surname><given-names>H</given-names></name></person-group>, <etal>et al.</etal>
<article-title>The prescribable drugs with efficacy in experimental epilepsies (PDE3) database for drug repurposing research in epilepsy</article-title>. <source/>Epilepsia. <year>2018</year>;<volume>59</volume>(<issue>2</issue>):<fpage>492</fpage>–<lpage>501</lpage>.<pub-id pub-id-type="pmid">29341109</pub-id></mixed-citation>
</ref>
<ref id="bibr65-1535759719895274">
<label>65</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Welzel</surname><given-names>L</given-names></name><name><surname>Twele</surname><given-names>F</given-names></name><name><surname>Schidlitzki</surname><given-names>A</given-names></name><name><surname>Tollner</surname><given-names>K</given-names></name><name><surname>Klein</surname><given-names>P</given-names></name><name><surname>Loscher</surname><given-names>W.</given-names></name></person-group>
<article-title>Network pharmacology for antiepileptogenesis: tolerability and neuroprotective effects of novel multitargeted combination treatments in nonepileptic vs. post-status epilepticus mice</article-title>. <source/>Epilepsy Res. <year>2019</year>;<volume>151</volume>:<fpage>48</fpage>–<lpage>66</lpage>.<pub-id pub-id-type="pmid">30831337</pub-id></mixed-citation>
</ref>
<ref id="bibr66-1535759719895274">
<label>66</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Atkin</surname><given-names>TA</given-names></name><name><surname>Maher</surname><given-names>CM</given-names></name><name><surname>Gerlach</surname><given-names>AC</given-names></name></person-group>, <etal>et al.</etal>
<article-title>A comprehensive approach to identifying repurposed drugs to treat SCN8A epilepsy</article-title>. <source/>Epilepsia. <year>2018</year>;<volume>59</volume>(<issue>4</issue>):<fpage>802</fpage>–<lpage>813</lpage>.<pub-id pub-id-type="pmid">29574705</pub-id></mixed-citation>
</ref>
<ref id="bibr67-1535759719895274">
<label>67</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pitsch</surname><given-names>J</given-names></name><name><surname>Kuehn</surname><given-names>JC</given-names></name><name><surname>Gnatkovsky</surname><given-names>V</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Anti-epileptogenic and anti-convulsive effects of fingolimod in experimental temporal lobe epilepsy</article-title>. <source/>Mole Neurobiol. <year>2019</year>;<volume>56</volume>(<issue>3</issue>):<fpage>1825</fpage>–<lpage>1840</lpage>.</mixed-citation>
</ref>
<ref id="bibr68-1535759719895274">
<label>68</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Citraro</surname><given-names>R</given-names></name><name><surname>Chimirri</surname><given-names>S</given-names></name><name><surname>Aiello</surname><given-names>R</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Protective effects of some statins on epileptogenesis and depressive-like behavior in WAG/Rij rats, a genetic animal model of absence epilepsy</article-title>. <source/>Epilepsia. <year>2014</year>;<volume>55</volume>(<issue>8</issue>):<fpage>1284</fpage>–<lpage>1291</lpage>.<pub-id pub-id-type="pmid">24962151</pub-id></mixed-citation>
</ref>
<ref id="bibr69-1535759719895274">
<label>69</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ceulemans</surname><given-names>B</given-names></name><name><surname>Boel</surname><given-names>M</given-names></name><name><surname>Leyssens</surname><given-names>K</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Successful use of fenfluramine as an add-on treatment for Dravet syndrome</article-title>. <source/>Epilepsia. <year>2012</year>;<volume>53</volume>(<issue>7</issue>):<fpage>1131</fpage>–<lpage>1139</lpage>.<pub-id pub-id-type="pmid">22554283</pub-id></mixed-citation>
</ref>
<ref id="bibr70-1535759719895274">
<label>70</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ceulemans</surname><given-names>B</given-names></name><name><surname>Schoonjans</surname><given-names>AS</given-names></name><name><surname>Marchau</surname><given-names>F</given-names></name><name><surname>Paelinck</surname><given-names>BP</given-names></name><name><surname>Lagae</surname><given-names>L</given-names></name></person-group>
<article-title>Five-year extended follow-up status of 10 patients with Dravet syndrome treated with fenfluramine</article-title>. <source/>Epilepsia. <year>2016</year>;<volume>57</volume>(<issue>7</issue>):<fpage>e129</fpage>–<lpage>e134</lpage>.<pub-id pub-id-type="pmid">27197941</pub-id></mixed-citation>
</ref>
<ref id="bibr71-1535759719895274">
<label>71</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lagae</surname><given-names>L</given-names></name><name><surname>Schoonjans</surname><given-names>AS</given-names></name><name><surname>Gammaitoni</surname><given-names>AR</given-names></name><name><surname>Galer</surname><given-names>BS</given-names></name><name><surname>Ceulemans</surname><given-names>B</given-names></name></person-group>
<article-title>A pilot, open-label study of the effectiveness and tolerability of low-dose ZX008 (fenfluramine HCl) in lennox-gastaut syndrome</article-title>. <source/>Epilepsia. <year>2018</year>;<volume>59</volume>(<issue>10</issue>):<fpage>1881</fpage>–<lpage>1888</lpage>.<pub-id pub-id-type="pmid">30146701</pub-id></mixed-citation>
</ref>
<ref id="bibr72-1535759719895274">
<label>72</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mullen</surname><given-names>SA</given-names></name><name><surname>Carney</surname><given-names>PW</given-names></name><name><surname>Roten</surname><given-names>A</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Precision therapy for epilepsy due to KCNT1 mutations: a randomized trial of oral quinidine</article-title>. <source/>Neurology. <year>2018</year>;<volume>90</volume>(<issue>1</issue>):<fpage>e67</fpage>–<lpage>e72</lpage>.<pub-id pub-id-type="pmid">29196578</pub-id></mixed-citation>
</ref>
<ref id="bibr73-1535759719895274">
<label>73</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Shineman</surname><given-names>DW</given-names></name><name><surname>Alam</surname><given-names>J</given-names></name><name><surname>Anderson</surname><given-names>M</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Overcoming obstacles to repurposing for neurodegenerative disease</article-title>. <source/>Ann Clin Transl Neurol. <year>2014</year>;<volume>1</volume>(<issue>7</issue>):<fpage>512</fpage>–<lpage>518</lpage>.<pub-id pub-id-type="pmid">25356422</pub-id></mixed-citation>
</ref>
<ref id="bibr74-1535759719895274">
<label>74</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ingusci</surname><given-names>S</given-names></name><name><surname>Cattaneo</surname><given-names>S</given-names></name><name><surname>Verlengia</surname><given-names>G</given-names></name><name><surname>Zucchini</surname><given-names>S</given-names></name><name><surname>Simonato</surname><given-names>M</given-names></name></person-group>
<article-title>A matter of genes: the hurdles of gene therapy for epilepsy</article-title>. <source/>Epilepsy Curr. <year>2019</year>;<volume>19</volume>(<issue>1</issue>):<fpage>38</fpage>–<lpage>43</lpage>.<pub-id pub-id-type="pmid">30838918</pub-id></mixed-citation>
</ref>
<ref id="bibr75-1535759719895274">
<label>75</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vezzani</surname><given-names>A</given-names></name></person-group>
<article-title>The promise of gene therapy for the treatment of epilepsy</article-title>. <source/>Expert Rev Neurother. <year>2007</year>;<volume>7</volume>(<issue>12</issue>):<fpage>1685</fpage>–<lpage>1692</lpage>.<pub-id pub-id-type="pmid">18052764</pub-id></mixed-citation>
</ref>
<ref id="bibr76-1535759719895274">
<label>76</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Vezzani</surname><given-names>A</given-names></name></person-group>
<article-title>Gene therapy in epilepsy</article-title>. <source/>Epilepsy Curr. <year>2004</year>;<volume>4</volume>(<issue>3</issue>):<fpage>87</fpage>–<lpage>90</lpage>.<pub-id pub-id-type="pmid">16059458</pub-id></mixed-citation>
</ref>
<ref id="bibr77-1535759719895274">
<label>77</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Riban</surname><given-names>V</given-names></name><name><surname>Fitzsimons</surname><given-names>HL</given-names></name><name><surname>During</surname><given-names>MJ</given-names></name></person-group>
<article-title>Gene therapy in epilepsy</article-title>. <source/>Epilepsia. <year>2009</year>;<volume>50</volume>(<issue>1</issue>):<fpage>24</fpage>–<lpage>32</lpage>.</mixed-citation>
</ref>
<ref id="bibr78-1535759719895274">
<label>78</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>O’Connor</surname><given-names>WM</given-names></name><name><surname>Davidson</surname><given-names>BL</given-names></name><name><surname>Kaplitt</surname><given-names>MG</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Adenovirus vector-mediated gene transfer into human epileptogenic brain slices: prospects for gene therapy in epilepsy</article-title>. <source/>Exp Neurol. <year>1997</year>;<volume>148</volume>(<issue>1</issue>):<fpage>167</fpage>–<lpage>178</lpage>.<pub-id pub-id-type="pmid">9398459</pub-id></mixed-citation>
</ref>
<ref id="bibr79-1535759719895274">
<label>79</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Freese</surname><given-names>A</given-names></name><name><surname>Kaplitt</surname><given-names>MG</given-names></name><name><surname>O’Connor</surname><given-names>WM</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Direct gene transfer into human epileptogenic hippocampal tissue with an adeno-associated virus vector: implications for a gene therapy approach to epilepsy</article-title>. <source/>Epilepsia. <year>1997</year>;<volume>38</volume>(<issue>7</issue>):<fpage>759</fpage>–<lpage>766</lpage>.<pub-id pub-id-type="pmid">9579902</pub-id></mixed-citation>
</ref>
<ref id="bibr80-1535759719895274">
<label>80</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Yenari</surname><given-names>MA</given-names></name><name><surname>Fink</surname><given-names>SL</given-names></name><name><surname>Sun</surname><given-names>GH</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Gene therapy with HSP72 is neuroprotective in rat models of stroke and epilepsy</article-title>. <source/>Ann Neurol. <year>1998</year>;<volume>44</volume>(<issue>4</issue>):<fpage>584</fpage>–<lpage>591</lpage>.<pub-id pub-id-type="pmid">9778256</pub-id></mixed-citation>
</ref>
<ref id="bibr81-1535759719895274">
<label>81</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Seki</surname><given-names>T</given-names></name><name><surname>Matsubayashi</surname><given-names>H</given-names></name><name><surname>Amano</surname><given-names>T</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Adenoviral gene transfer of aspartoacylase into the tremor rat, a genetic model of epilepsy, as a trial of gene therapy for inherited epileptic disorder</article-title>. <source/>Neurosci Lett. <year>2002</year>;<volume>328</volume>(<issue>3</issue>):<fpage>249</fpage>–<lpage>252</lpage>.<pub-id pub-id-type="pmid">12147318</pub-id></mixed-citation>
</ref>
<ref id="bibr82-1535759719895274">
<label>82</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kanter-Schlifke</surname><given-names>I</given-names></name><name><surname>Georgievska</surname><given-names>B</given-names></name><name><surname>Kirik</surname><given-names>D</given-names></name><name><surname>Kokaia</surname><given-names>M</given-names></name></person-group>
<article-title>Seizure suppression by GDNF gene therapy in animal models of epilepsy</article-title>. <source/>Mol Ther. <year>2007</year>;<volume>15</volume>(<issue>6</issue>):<fpage>1106</fpage>–<lpage>1113</lpage>.<pub-id pub-id-type="pmid">17387333</pub-id></mixed-citation>
</ref>
<ref id="bibr83-1535759719895274">
<label>83</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Richichi</surname><given-names>C</given-names></name><name><surname>Lin</surname><given-names>EJ</given-names></name><name><surname>Stefanin</surname><given-names>D</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Anticonvulsant and antiepileptogenic effects mediated by adeno-associated virus vector neuropeptide Y expression in the rat hippocampus</article-title>. <source/>J Neurosci. <year>2004</year>;<volume>24</volume>(<issue>12</issue>):<fpage>3051</fpage>–<lpage>3059</lpage>.<pub-id pub-id-type="pmid">15044544</pub-id></mixed-citation>
</ref>
<ref id="bibr84-1535759719895274">
<label>84</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Noe</surname><given-names>F</given-names></name><name><surname>Nissinen</surname><given-names>J</given-names></name><name><surname>Pitkanen</surname><given-names>A</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Gene therapy in epilepsy: the focus on NPY</article-title>. <source/>Peptides. <year>2007</year>;<volume>28</volume>(<issue>2</issue>):<fpage>377</fpage>–<lpage>383</lpage>.<pub-id pub-id-type="pmid">17196301</pub-id></mixed-citation>
</ref>
<ref id="bibr85-1535759719895274">
<label>85</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Noe</surname><given-names>F</given-names></name><name><surname>Pool</surname><given-names>AH</given-names></name><name><surname>Nissinen</surname><given-names>J</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Neuropeptide Y gene therapy decreases chronic spontaneous seizures in a rat model of temporal lobe epilepsy</article-title>. <source/>Brain J Neurol. <year>2008</year>;<volume>131</volume>(<issue>Pt 6</issue>):<fpage>1506</fpage>–<lpage>1515</lpage>.</mixed-citation>
</ref>
<ref id="bibr86-1535759719895274">
<label>86</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Ledri</surname><given-names>LN</given-names></name><name><surname>Melin</surname><given-names>E</given-names></name><name><surname>Christiansen</surname><given-names>SH</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Translational approach for gene therapy in epilepsy: model system and unilateral overexpression of neuropeptide Y and Y2 receptors</article-title>. <source/>Neurobiol Dis. <year>2016</year>;<volume>86</volume>:<fpage>52</fpage>–<lpage>61</lpage>.<pub-id pub-id-type="pmid">26607785</pub-id></mixed-citation>
</ref>
<ref id="bibr87-1535759719895274">
<label>87</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Powell</surname><given-names>KL</given-names></name><name><surname>Fitzgerald</surname><given-names>X</given-names></name><name><surname>Shallue</surname><given-names>C</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Gene therapy mediated seizure suppression in genetic generalised epilepsy: neuropeptide Y overexpression in a rat model</article-title>. <source/>Neurobiol Dis. <year>2018</year>;<volume>113</volume>:<fpage>23</fpage>–<lpage>32</lpage>.<pub-id pub-id-type="pmid">29414380</pub-id></mixed-citation>
</ref>
<ref id="bibr88-1535759719895274">
<label>88</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Wykes</surname><given-names>RC</given-names></name><name><surname>Heeroma</surname><given-names>JH</given-names></name><name><surname>Mantoan</surname><given-names>L</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Optogenetic and potassium channel gene therapy in a rodent model of focal neocortical epilepsy</article-title>. <source/>Sci Transl Med. <year>2012</year>;<volume>4</volume>(<issue>161</issue>):<fpage>161ra152</fpage>.</mixed-citation>
</ref>
<ref id="bibr89-1535759719895274">
<label>89</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Young</surname><given-names>D</given-names></name><name><surname>Fong</surname><given-names>DM</given-names></name><name><surname>Lawlor</surname><given-names>PA</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Adenosine kinase, glutamine synthetase and EAAT2 as gene therapy targets for temporal lobe epilepsy</article-title>. <source/>Gene Ther. <year>2014</year>;<volume>21</volume>(<issue>12</issue>):<fpage>1029</fpage>–<lpage>1040</lpage>.<pub-id pub-id-type="pmid">25231174</pub-id></mixed-citation>
</ref>
<ref id="bibr90-1535759719895274">
<label>90</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Lieb</surname><given-names>A</given-names></name><name><surname>Qiu</surname><given-names>Y</given-names></name><name><surname>Dixon</surname><given-names>CL</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Biochemical autoregulatory gene therapy for focal epilepsy</article-title>. <source/>Nat Med. <year>2018</year>;<volume>24</volume>(<issue>9</issue>):<fpage>1324</fpage>–<lpage>1329</lpage>.<pub-id pub-id-type="pmid">29988123</pub-id></mixed-citation>
</ref>
<ref id="bibr91-1535759719895274">
<label>91</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Snowball</surname><given-names>A</given-names></name><name><surname>Chabrol</surname><given-names>E</given-names></name><name><surname>Wykes</surname><given-names>RC</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Epilepsy gene therapy using an engineered potassium channel</article-title>. <source/>J Neurosci. <year>2019</year>;<volume>39</volume>(<issue>16</issue>):<fpage>3159</fpage>–<lpage>3169</lpage>.<pub-id pub-id-type="pmid">30755487</pub-id></mixed-citation>
</ref>
<ref id="bibr92-1535759719895274">
<label>92</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Patricio</surname><given-names>MI</given-names></name><name><surname>Barnard</surname><given-names>AR</given-names></name><name><surname>Green</surname><given-names>AL</given-names></name><name><surname>During</surname><given-names>MJ</given-names></name><name><surname>Sen</surname><given-names>A</given-names></name><name><surname>MacLaren</surname><given-names>RE</given-names></name></person-group>
<article-title>A clinical-grade gene therapy vector for pharmacoresistant epilepsy successfully overexpresses NPY in a human neuronal cell line</article-title>. <source/>Seizure. <year>2018</year>;<volume>55</volume>:<fpage>25</fpage>–<lpage>29</lpage>.<pub-id pub-id-type="pmid">29367144</pub-id></mixed-citation>
</ref>
<ref id="bibr93-1535759719895274">
<label>93</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Kullmann</surname><given-names>DM</given-names></name><name><surname>Schorge</surname><given-names>S</given-names></name><name><surname>Walker</surname><given-names>MC</given-names></name><name><surname>Wykes</surname><given-names>RC</given-names></name></person-group>
<article-title>Gene therapy in epilepsy-is it time for clinical trials?</article-title>
<source/>Nat Rev Neurol. <year>2014</year>;<volume>10</volume>(<issue>5</issue>):<fpage>300</fpage>–<lpage>304</lpage>.<pub-id pub-id-type="pmid">24638133</pub-id></mixed-citation>
</ref>
<ref id="bibr94-1535759719895274">
<label>94</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Simonato</surname><given-names>M</given-names></name></person-group>
<article-title>Gene therapy for epilepsy</article-title>. <source/>Epilepsy Behav. <year>2014</year>;<volume>38</volume>:<fpage>125</fpage>–<lpage>130</lpage>.<pub-id pub-id-type="pmid">24100249</pub-id></mixed-citation>
</ref>
<ref id="bibr95-1535759719895274">
<label>95</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Mendell</surname><given-names>JR</given-names></name><name><surname>Al-Zaidy</surname><given-names>S</given-names></name><name><surname>Shell</surname><given-names>R</given-names></name></person-group>, <etal>et al.</etal>
<article-title>Single-dose gene-replacement therapy for spinal muscular atrophy</article-title>. <source/>N Engl J Med. <year>2017</year>;<volume>377</volume>(<issue>18</issue>):<fpage>1713</fpage>–<lpage>1722</lpage>.<pub-id pub-id-type="pmid">29091557</pub-id></mixed-citation>
</ref>
<ref id="bibr96-1535759719895274">
<label>96</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Srivastava</surname><given-names>PK</given-names></name><name><surname>van Eyll</surname><given-names>J</given-names></name><name><surname>Godard</surname><given-names>P</given-names></name></person-group>, <etal>et al.</etal>
<article-title>A systems-level framework for drug discovery identifies Csf1 R as an anti-epileptic drug target</article-title>. <source/>Nat Communicat. <year>2018</year>;<volume>9</volume>(<issue>1</issue>):<fpage>3561</fpage>.</mixed-citation>
</ref>
<ref id="bibr97-1535759719895274">
<label>97</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Failli</surname><given-names>M</given-names></name><name><surname>Paananen</surname><given-names>J</given-names></name><name><surname>Fortino</surname><given-names>V</given-names></name></person-group>
<article-title>Prioritizing target-disease associations with novel safety and efficacy scoring methods</article-title>. <source/>Sci Rep. <year>2019</year>;<volume>9</volume>(<issue>1</issue>):<fpage>9852</fpage>.<pub-id pub-id-type="pmid">31285471</pub-id></mixed-citation>
</ref>
<ref id="bibr98-1535759719895274">
<label>98</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Pitkanen</surname><given-names>A</given-names></name><name><surname>Ekolle Ndode-Ekane</surname><given-names>X</given-names></name><name><surname>Lapinlampi</surname><given-names>N</given-names></name><name><surname>Puhakka</surname><given-names>N</given-names></name></person-group>
<article-title>Epilepsy biomarkers - toward etiology and pathology specificity</article-title>. <source/>Neurobiol Dis. <year>2019</year>;<volume>123</volume>:<fpage>42</fpage>–<lpage>58</lpage>.<pub-id pub-id-type="pmid">29782966</pub-id></mixed-citation>
</ref>
<ref id="bibr99-1535759719895274">
<label>99</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Burneo</surname><given-names>JG</given-names></name></person-group>
<article-title>Neurocysticercosis-related epilepsy</article-title>. <source/>Epilepsy Behav. <year>2017</year>;<volume>76</volume>:<fpage>145</fpage>.<pub-id pub-id-type="pmid">28867576</pub-id></mixed-citation>
</ref>
<ref id="bibr100-1535759719895274">
<label>100</label>
<mixed-citation publication-type="book">
<collab collab-type="author"><italic>Epilepsy: a public health imperative</italic></collab>. <publisher-loc>Geneva</publisher-loc>: <publisher-name>World Health Organization</publisher-name>; <year>2019</year>.</mixed-citation>
</ref>
<ref id="bibr101-1535759719895274">
<label>101</label>
<mixed-citation publication-type="journal">
<person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>D</given-names></name><name><surname>Friedman</surname><given-names>D</given-names></name><name><surname>Dichter</surname><given-names>MA</given-names></name></person-group>
<article-title>Anti-epileptogenic clinical trial designs in epilepsy: issues and options</article-title>. <source/>Neurotherapeutics. <year>2014</year>;<volume>11</volume>(<issue>2</issue>):<fpage>401</fpage>–<lpage>411</lpage>.<pub-id pub-id-type="pmid">24420312</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>